Key Finding
No strong consistent positive evidence pattern was detected.
Interventions with strongest consistent evidence
Strongest consistent evidence
Interpretation
The current evidence does not yet show a clear consistent-benefit pattern.
Cardiometabolic Risk in Diabetes: Blood Pressure, Cholesterol, and Heart Outcomes
Evidence related to cardiometabolic risk
Evidence related to blood pressure, lipid profile, cardiovascular risk, cardiovascular events, and cardiometabolic risk markers in diabetes.
Crea tu Evidence Workspace
Guarda evidencia sobre los temas que te importan.
9
Studies
12
Evidence Pairs
Moderate Research Support
Relationship Confidence: 61/100
Evidence summary for AI and search
Among 9 indexed studies and 6 interventions, the strongest signals are summarized from deterministic graph patterns. Exercise therapy has been studied often, while GLP-1 receptor agonists appears to have stronger current evidence signals.
- No strong consistent positive evidence pattern was detected.
- Some evidence is positive, but results are not consistent across all studies.
- Early findings are encouraging, but stronger trials are needed.
Dediabetes summarizes indexed research evidence for education and discovery. This content is not medical advice and should not replace guidance from a qualified clinician.
Supporting Studies
9
Research documents analyzed
Evidence Pairs
12
Intervention-outcome relationships
Latest Publication
May 2026
Evidence Snapshot
Qualitative overview of the evidence landscape
Low Confidence
Based on 9 studies, moderate evidence suggests Exercise therapy, SGLT2 inhibitors, GLP-1 receptor agonists are the strongest-supported interventions for cardiometabolic risk.
Evidence Intelligence™
Evidence Snapshot
A structured summary of where the evidence is strongest, mixed, or still emerging.
Evidence at a Glance
9
Studies
6
Interventions
8
Outcomes
0
Strong evidence signals
2
Mixed evidence areas
Evidence freshness
May 2026
Latest indexed
Evidence Story
Cardiometabolic Risk evidence appears to center on GLP-1 receptor agonists.
Among 9 indexed studies and 6 interventions, the strongest signals are summarized from deterministic graph patterns. Exercise therapy has been studied often, while GLP-1 receptor agonists appears to have stronger current evidence signals.
- No strong consistent positive evidence pattern was detected.
- Some evidence is positive, but results are not consistent across all studies.
- Early findings are encouraging, but stronger trials are needed.
Caution
This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.
Freshness
Latest indexed evidence: May 2026
Supporting Evidence
Mixed or conflicting evidence
Some evidence is positive, but results are not consistent across all studies.
Areas where results are mixed
Why it matters
Mixed results suggest effects may depend on population, comparator, duration, or study design.
Interpretation
Exercise therapy is mixed in the currently indexed evidence.
Caution
Some supporting studies reported neutral, negative, or mixed findings.
Top entities
Exercise therapy
Metformin
Exercise therapy
2 studies
EvidenceScore™
69/100
ConsistencyScore™
73/100
Why this appears here
Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present
Evidence basis: 9 evidence pairs - 6 studies
Promising but understudied
Early findings are encouraging, but stronger trials are needed.
Promising areas needing more evidence
Why it matters
Promising signals can guide further review, but they should not be treated as settled evidence.
Interpretation
SGLT2 inhibitors may have a beneficial signal, but the evidence base is still developing.
Caution
Current support is limited by study volume, RCT depth, or evidence strength.
Top entities
SGLT2 inhibitors
GLP-1 receptor agonists
SGLT2 inhibitors
2 studies
EvidenceScore™
69/100
ConsistencyScore™
63/100
Why this appears here
Positive effect signalLimited study volumeFew randomized trialsEmerging Or Limited Strength
Evidence basis: 9 evidence pairs - 6 studies
Practical Questions
Organized using the Dediabetes Evidence Intelligence™ framework.
Does Exercise therapy improve systolic blood pressure?
intervention effectivenessModerate Evidence
Exercise therapy may improve Systolic blood pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Exercise therapy
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 2 studies
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does Exercise therapy improve diastolic blood pressure?
intervention effectivenessModerate Evidence
Current evidence does not show a clear benefit of Exercise therapy for Diastolic blood pressure.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: Some evidence reported benefits while other evidence found little or no effect.
Ranked evidence signals
- 1
Exercise therapy
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 2 studies
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does SGLT2 inhibitors improve all-cause mortality?
intervention effectivenessModerate Evidence
SGLT2 inhibitors may improve All-cause mortality.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: Some evidence reported benefits while other evidence found little or no effect.
Ranked evidence signals
- 1
SGLT2 inhibitors
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 2 studies
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does GLP-1 receptor agonists improve systolic blood pressure?
intervention effectivenessEmerging Evidence
GLP-1 receptor agonists appears to improve Systolic blood pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
GLP-1 receptor agonists
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Metformin improve systolic blood pressure?
intervention effectivenessEmerging Evidence
Metformin appears to improve Systolic blood pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Metformin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Metformin improve total cholesterol?
intervention effectivenessEmerging Evidence
Current evidence does not show a clear benefit of Metformin for Total cholesterol.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Metformin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Metformin improve ldl cholesterol?
intervention effectivenessEmerging Evidence
Metformin appears to improve LDL cholesterol.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Metformin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Metformin improve hdl cholesterol?
intervention effectivenessEmerging Evidence
Metformin appears to improve HDL cholesterol.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Metformin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Studied interventions
Interventions studied in relation to this topic
Exercise therapy
2 studies
View evidence
SGLT2 inhibitors
2 studies
View evidence
GLP-1 receptor agonists
1 study
View evidence
Metformin
1 study
View evidence
Pioglitazone
1 study
View evidence
Resistance training
1 study
View evidence
Note: ImpactScore™, EvidenceScore™, and ConsistencyScore™ values are provided by the Evidence Intelligence™ read model when available. Click any option to explore the supporting research in our archive.
Strongest evidence signals
Key patterns and insights identified across the research landscape
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Neutral signal
Exercise therapy shows limited or neutral effect on Diastolic blood pressure
Exercise therapy → Diastolic blood pressure
Across 2 studies, Exercise therapy shows a neutral signal for Diastolic blood pressure.
2 studies
EvidenceScore™: 69/100
Moderate positive signal
Exercise therapy may improve Systolic blood pressure
Exercise therapy → Systolic blood pressure
Across 2 studies, Exercise therapy shows a consistent moderate positive signal for Systolic blood pressure.
2 studies
EvidenceScore™: 69/100
Moderate positive signal
SGLT2 inhibitors may improve All-cause mortality
SGLT2 inhibitors → All-cause mortality
Across 2 studies, SGLT2 inhibitors shows a moderate positive signal for All-cause mortality.
2 studies
EvidenceScore™: 69/100
Strong positive signal
GLP-1 receptor agonists shows strong evidence for improving Systolic blood pressure
GLP-1 receptor agonists → Systolic blood pressure
Across 1 study, GLP-1 receptor agonists shows a strong positive signal for Systolic blood pressure.
1 studies
EvidenceScore™: 59/100
Strong positive signal
Metformin shows strong evidence for improving HDL cholesterol
Metformin → HDL cholesterol
Across 1 study, Metformin shows a strong positive signal for HDL cholesterol.
1 studies
EvidenceScore™: 59/100
Supporting Research
Selected studies that best represent the evidence behind this topic.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes
May 16, 2026
Highly relevant
Interventions:
Outcomes:
Click any study to view the full research summary, or click interventions and outcomes to filter the archive.
Explore all supporting studies
Browse the complete evidence archive for this topic, including interventions, outcomes, and related research.
View All Supporting StudiesFilter by study type, publication date, effect size, and more to refine your research